Longeveron Inc.
LGVN · XNASCIK 1721484fmd_1WRNQYS7D29P3F43JZEKKZG919Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 6 | 1 | 1 | 1 | 2 | 1 |
| Cost of revenue | 4 | 1 | 1 | 0 | 1 | 0 |
| Gross profit | 2 | 1 | 0 | 0 | 2 | 1 |
| Research and development | 3 | 7 | 9 | 9 | 8 | 12 |
| Selling, general and administrative | 3 | 11 | 9 | 12 | – | – |
| Total operating expenses | 6 | 18 | 19 | 21 | 18 | 24 |
| Compensation and benefits | – | 1 | – | – | – | – |
| Operating income | (4) | (17) | (18) | (21) | (17) | (23) |
| Interest expense | 0 | 0 | 1 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | (1) | (0) | 1 | 1 |
| Income tax expense | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (4) | (17) | (19) | – | – | – |
| Net income | (4) | (17) | (19) | (21) | (16) | (23) |
| Net income to common shareholders | – | – | (19) | (22) | (25) | (23) |